IFNAR1 and malignant colon neoplasm: Inactivation of IFNAR1 in CTLs was reported to limit their survival within the TME and undermine the efficacy of chimeric antigen receptor (CAR) T cell treatment in colon cancer models, while genetic stabilization of IFNAR1 improved CTL viability and response to both CAR T cell and anti-PD-1 therapy [103].